McKesson (MCK)
(Delayed Data from NYSE)
$482.27 USD
-6.51 (-1.33%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $482.44 +0.17 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$482.27 USD
-6.51 (-1.33%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $482.44 +0.17 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
Zacks News
Fresenius Medical's (FMS) New HHD Device to Increase Portability
by Zacks Equity Research
Fresenius Medical (FMS) gets FDA clearance for Versi HD with GuideMe Software, a portable, home hemodialysis device with an easy-to-use graphical interface providing easier training experiences.
NextGen (NXGN) Behavioral Health Suite to Address Mental Health
by Zacks Equity Research
NextGen's (NXGN) Behavioral Health Suite is expected to ease state reporting and enable the secure sharing of patient information across providers.
Should Value Investors Buy McKesson (MCK) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why You Should Invest in HealthEquity (HQY) Stock Now
by Zacks Equity Research
HealthEquity's (HQY) strength in HSA raises optimism about the stock.
Masimo's (MASI) PVi Favored by Study for GDFT in Elderly Patients
by Zacks Equity Research
Masimo's (MASI) non-invasive, continuous PVi is expected to reduce cardiopulmonary complications and fluid administered in elderly patients during GI surgery.
Reasons to Add Veeva Systems (VEEV) Stock to Your Portfolio
by Zacks Equity Research
Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.
Reasons to Retain West Pharmaceutical (WST) Stock for Now
by Zacks Equity Research
West Pharmaceutical's (WST) strength in its proprietary products segment raises optimism about the stock.
Nevro's (NVRO) New Data Supports SCS Therapy for PDN Treatment
by Zacks Equity Research
Nevro's (NVRO) latest 24-month data demonstrates the benefits of high-frequency 10 kHz SCS implant for durable pain relief and significant improvements in patient condition post-implantation.
Is McKesson (MCK) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how McKesson (MCK) and Medpace (MEDP) have performed compared to their sector so far this year.
McKesson (MCK) & Genpact Extend Tie Up to Improve Workflow
by Zacks Equity Research
McKesson's (MCK) latest partnership extension is likely to transform its finance operations for enhanced service and competitive growth.
AngioDynamics' (ANGO) New FDA Recognition to Boost Treatment
by Zacks Equity Research
The FDA's grant of the Breakthrough Device designation for AngioDynamics' (ANGO) AngioVac is likely to remove thrombus and embolic material and minimize blood loss via blood recirculation.
Patterson Companies (PDCO) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Patterson Companies' (PDCO) broad product line.
West Pharmaceutical (WST) Hits 52-Week High: More Room to Grow?
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
Cardinal Health (CAH) Beats on Q4 Earnings, Ups '24 EPS View
by Zacks Equity Research
Cardinal Health's (CAH) fiscal fourth-quarter results benefit from the Pharmaceutical segment's solid performance.
Nevro's (NVRO) Latest Launch to Customize Chronic Pain Treatment
by Zacks Equity Research
Nevro's (NVRO) HFX Connect system is expected to treat individual patients per their requirements with 35 pre-programmed customizable plans.
3 Stocks to Buy on Recent Dividend Hikes
by Derek Lewis
Dividend hikes reflect a company's commitment to returning value to shareholders, undoubtedly encouraging. And recently, all three of these companies have boosted their payouts.
3 Reasons to Retain DaVita (DVA) Stock to Your Portfolio
by Zacks Equity Research
DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.
Reasons to Add Patterson Companies (PDCO) to Your Portfolio Now
by Zacks Equity Research
Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.
Add These 4 Stocks With Impressive Interest Coverage Ratio
by Sumit Singh
A company that is capable of generating earnings well above its interest expense can withstand financial hardship. MOH, DAL, ATO and MCK are strong enough to meet financial obligations.
Merit Medical (MMSI) Completes Enrollment in WRAPSODY Study
by Zacks Equity Research
Merit Medical (MMSI) is evaluating its device for treating stenosis/occlusion, WRAPSODY, in a pivotal study on patients undergoing hemodialysis. Primary data from the study is expected after six months.
McKesson (MCK) Q1 Earnings Beat Estimates, U.S. Sales Strong
by Zacks Equity Research
McKesson's (MCK) fiscal first-quarter 2024 results benefit from growth in the United States. Divestment hurts the International segment.
McKesson (MCK) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for McKesson (MCK) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
McKesson (MCK) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of 24.27% and 6.55%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
DaVita (DVA) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Improvement in U.S. dialysis treatments per day and cost-saving initiatives are likely to have boosted DaVita's (DVA) second quarter's top line.
Medical Device Aug 2 Earnings Roster: MCK, FMS & GKOS
by Indrajit Bandyopadhyay
Medical Device players are expected to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how MCK, FMS and GKOS are likely to have performed this time.